Roflumilast (Daliresp®) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial.

Sarcoidosis Vasc Diffuse Lung Dis · 2021 · PMC8552567 · PMID 34744427

Europe PMC DOI

hedged sentences

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

borderline significantp=0.07so close (0.05 < p ≤ 0.1)

For the LCQ, there was borderline significant improvement in the LCQ for the ROF patients ( Figure 3A , p=0.07), but not for the PLA patients ( Figure 3B ).

also in 11,409 other papers

of borderline significanceno p-value reported

There was a 1.6-point increase in the LCQ score for the ROF treated patients which was of borderline significance.

also in 2,624 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.